Recombinant EGFR (Panitumumab Biosimilar) antibody
Reactivity: Human
FACS, in vivo
Host: Mouse
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all EGFR (Panitumumab Biosimilar) products
- EGFR (Panitumumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This EGFR (Panitumumab Biosimilar) antibody is un-conjugated
- Application
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- Purpose
- Panitumumab Biosimilar, Human EGFR/ErbB-1/HER1 Monoclonal Antibody
- Specificity
- The monoclonal antibody panitumumab biosimilar specifically binds to the human EGFR, ErbB-1 and HER1.
- Characteristics
- Recombinant Humanized IgG2 Monoclonal Antibody.
- Purification
- Protein A affinity column
- Purity
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- Sterility
- 0.2 μm filtered
- Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method.
- Immunogen
- The monoclonal antibody panitumumab biosimilar was produced in the Panitumumab biosimilar CHO stable cell line.
- Isotype
- IgG2 kappa
-
-
- Application Notes
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by panitumumab.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- PBS, pH 7.4, no stabilizers or preservatives.
- Preservative
- Without preservative
- Handling Advice
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- Expiry Date
- 12 months
-
- Target
- EGFR (Panitumumab Biosimilar)
- Abstract
- EGFR (Panitumumab Biosimilar) Products
- Target Type
- Biosimilar
- Background
- Panitumumab, a fully anti-EGFR (epidermal growth factor receptor, EGF receptor, ErbB-1 and HER1 in humans) human monoclonal antibody, is used for the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS".
-
You are here:
